TIL Therapy in Lung Cancer: Current Progress and Perspectives

Abstract Lung cancer remains the most prevalent malignant tumor worldwide and is the leading cause of cancer‐related mortality. Although immune checkpoint blockade has revolutionized the treatment of advanced lung cancer, many patients still do not respond well, often due to the lack of functional T cell infiltration. Adoptive cell therapy (ACT) using expanded immune cells has emerged as an important therapeutic modality. Tumor‐infiltrating lymphocytes (TIL) therapy is one form of ACT involving the administration of expanded and activated autologous T cells derived from surgically resected cancer tissues and reinfusion into patients and holds great therapeutic potential for lung cancer. In this review, TIL therapy is introduced and its suitability for lung cancer is discussed. Then its historical and clinical developments are summarized, and the methods developed up‐to‐date to identify tumor‐recognizing TILs and optimize TIL composition. Some perspectives toward future TIL therapy for lung cancer are also provided.